PIEMONTE

Phase 3Small molecule

EEMS

PIEMONTE is one of 51 small molecule programs targeting Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetes MellitusRecruiting

Diabetes MellitusPhase 3

Recruiting

Competition

Competitive Landscape

111 competitors in Diabetes Mellitus

#DrugCompanyPhaseTrials

Rifadin

Intropin

Actigall

Estrace

Neoral

Brilinta

Avelox

Invokana

Synthroid

IInstitut Jerome Lejeune

Approved

—10

Adipex-P

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Diabetes Mellitus

NCT05028140

Clinical

Trials by Indication[1]

Diabetes Mellitus1 trial

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

Recruiting·EEMS·Phase 3·NCT05028140·480 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PIEMONTE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PIEMONTE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PIEMONTE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEMS

PIEMONTE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News